

### UNITED STATES PATENT AND TRADEMARK OFFICE



APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/530,747	10/23/2000	Christoph Kessler	4817/OR	5088
22829	7590 12/31/2002			
ROCHE MOLECULAR SYSTEMS INC PATENT LAW DEPARTMENT 1145 ATLANTIC AVENUE			EXAMINER	
			SAKELARIS, SALLY A	
ALAMEDA, (	ALAMEDA, CA 94501		ART UNIT	PAPER NUMBER
			1634	•
			DATE MAILED: 12/31/2002	П

Please find below and/or attached an Office communication concerning this application or proceeding.

		Application No.	Applicant(s)				
Office Action Summary							
		09/530,747	KESSLER ET AL.				
		Examiner	Art Unit				
	The MAILING DATE of this communication app	Sally A Sakelaris ears on the cover sheet with the co	1634				
Period for Reply							
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status							
1)⊠	Responsive to communication(s) filed on 16 C	ctober 2002 .					
2a) <u></u> □	This action is <b>FINAL</b> . 2b)⊠ This	s action is non-final.					
3)							
closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>							
4) Claim(s) 1-9 is/are pending in the application.							
4a) Of the above claim(s) is/are withdrawn from consideration.							
5) Claim(s) is/are allowed.							
6)	6)⊠ Claim(s) <u>1-9</u> is/are rejected.						
7)	Claim(s) is/are objected to.						
8) Claim(s) are subject to restriction and/or election requirement.							
Application Papers							
9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.							
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).  11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.							
If approved, corrected drawings are required in reply to this Office action.							
12) The oath or declaration is objected to by the Examiner.							
Priority under 35 U.S.C. §§ 119 and 120							
13)⊠ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).							
a)⊠ All b)□ Some * c)□ None of:							
1. Certified copies of the priority documents have been received.							
2. Certified copies of the priority documents have been received in Application No							
<ul> <li>3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).</li> <li>* See the attached detailed Office action for a list of the certified copies not received.</li> </ul>							
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).							
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.							
Attachment(	s)	2 -					
2) 🔲 Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal Pa	PTO-413) Paper No(s) stent Application (PTO-152)				

Application/Control Number: 09/530,747

Art Unit: 1634

#### **DETAILED ACTION**

### Response to Arguments

1. This action is in response to Paper No. 16, filed October 16, 2002. Applicants arguments presented in the response of Paper No. 12 have been fully considered and are persuasive to overcome all grounds of previous rejection. All rejections not reiterated herein are hereby withdrawn. This action is non-final.

## Response to Amendment

2. Applicants' amendments to claim 1 is acknowledged and entered. Accordingly, claims 1-9 are currently pending and under examination.

# THE FOLLOWING ARE NEW GROUNDS OF REJECTION:

# Claim Rejections - 35 USC § 112

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:


The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-9 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A. Please see the figure below for clarification of the following first rejection.

Application/Control Number: 09/530,747

Art Unit: 1634



### A. (Continued)

Claims 1-9 are indefinite over the recitation of "one of which[primer] can bind to a first binding sequence A." This instruction will result in the 3' primer extension in the direction of A's 5' end. Likewise, Claim 1 is further indefinite over the recitation of "the other[primer] can bind to a second binding sequence C' which is essentially complementary to a sequence C which is located in the 3' direction from A." As can been seen above, if the second primer binds to C' and the first primer binds to A, an overlapping product will not exist. Applicant should amend the claim to clarify the resulting amplification product.

B. Claims 1-9 are indefinite over the recitation of "aid of." It is not clear how the two primers are "aiding" this process being claimed. Applicant could amend this phrase by deleting "with the aid of" and adding "by amplifying said section of nucleic acid with." Alternatively, applicant may amend how they see fit in order to clarify this claim.

Art Unit: 1634

C. Claims 1-9 are indefinite over the recitation of "can bind"(3<sup>rd</sup> line), "can bind"(4<sup>th</sup> line), and "can bind"(7<sup>th</sup> line) as it is unclear what implication "can" entails. Applicant could amend the aforementioned phrasings by deleting the "can bind"(Lines 3,4,and 7) and adding: "binds"(3<sup>rd</sup> line), "which binds"(4<sup>th</sup> line), and "binds"(7<sup>th</sup> line) respectively. Alternatively, applicant may amend the claim how they see fit in order to clarify.

Any inquiry concerning this communication or earlier communication from the examiner should be directed to Sally Sakelaris whose telephone number is (703) 306-0284. The examiner can normally be reached on Monday-Friday from 8:00AM-5:00PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, W.Gary Jones, can be reached on (703)308-1152. The fax number for the Technology Center is (703)305-3014 or (703)305-4242.

Any inquiry of a general nature or relating to the status of this application should be directed to Chantae Dessau whose telephone number is (703)605-1237.

12/30/2002

Sally Sakelaris

CARLA J. MYERS PRIMARY EXAMINER